CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 448 enrolled
Drug / intervention
Artefenomel 800mg: piperaquine 640mg +2 moredrug
Likely dose
Artefenomel 800mg: piperaquine 640mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02083380
NCT02083380Phase 3Completed

Randomised Phase IIb Study of Efficacy, Safety, Tolerability & Pharmacokinetics of a Single Dose Regimen of Artefenomel (OZ439) in Loose Combination With Piperaquine in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria.

Medicines for Malaria Venture·interventional·Posted Mar 11, 2014·Updated Mar 10, 2017

In Brief

A Phase 3 clinical trial evaluating Artefenomel 800mg: piperaquine 640mg, Artefenomel 800mg: piperaquine 960mg, and 1 other intervention for Uncomplicated Plasmodium Falciparum Malaria. Completed, enrolled 448 participants across 9 sites in 7 countries.

Detailed Summary

A randomised, double-blind single-dose study to determine the efficacy, safety, tolerability and pharmacokinetics of OZ439 (artefenomel) in combination with piperaquine (PQP) in patients \> 0.5 years and \<= 70 years of age with uncomplicated Plasmodium falciparum malaria in Africa and Asia (Vietnam). Interim analyses for futility were planned. Adults and children will be included through progressive step-down in age following safety review by an independent safety monitoring board (ISMB). If the study were to meets its efficacy objectives, this will inform dose setting for Phase III studies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBenin, Burkina Faso, Democratic Republic of the Congo, Gabon, Mozambique, Uganda, Vietnam
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 11, 2014
Enrollment StartJul 1, 2014
Primary CompletionOct 1, 2015
Study CompletionNov 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 12.3 years ago

Interventions

Artefenomel 800mg: piperaquine 640mgdrug

Active, loose combination

Artefenomel 800mg: piperaquine 960mgdrug

Active, loose combination

Artefenomel 800mg: piperaquine 1440mgdrug

Active, loose combination